Радиочастотная катетерная аблация желудочковых тахикардий у пациентов с хронической сердечной недостаточностью

Данная обзорная статья посвящена месту радиочастотной катетерной аблации в профилактике и лечении желудочковых тахикардий у пациентов с ишемической кардиомиопатией и хронической сердечной недостаточностью, а также оценке влияния интервенционного лечения желудочковой тахикардии на течение хронической сердечной недостаточности и прогноз пациентов с систолической дисфункцией левого желудочка. Имплантируемые кардиовертеры-дефибриляторы в большинстве своем успешно предотвращают внезапную сердечную смерть, связанную с желудочковой тахикардией, однако повторяющиеся шоки имплантируемого кардиовертер-дефибрилятора остаются большой проблемой в лечении данной категории пациентов. Резерв антиаритмической терапии у пациентов с хронической сердечной недостаточностью существенно ограничен, радиочастотная катетерная аблация и стереотаксическая радиоаблация являются эффективной стратегией лечения пациентов в условиях хронической сердечной недостаточности.

1. Cronin EM, Bogun FM, Maury P, et al. 2019 HRS/ EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias [published correction appears in Europace. 2019 Aug 1;21(8):1144] [published correction appears in J Arrhythm. 2020 Jan 12;36(1):214] [published correction appears in Europace. 2020 Mar 1;22(3):505]. Europace. 2019;21(8):1143-1144. doi:10.1093/europace/euz132

2. Anderson KP. Sudden cardiac death unresponsive to implantable defibrillator therapy: an urgent target for clinicians, industry and government. J Interv Card Electrophysiol. 2005 Nov;2(14):71-8. doi: 10.1007/s10840-005-4547-9.

3. Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980;303:322–4. doi: 10.1056/NEJM198008073030607.

4. Sears SF, Conti JB. Quality of life and psychological functioning of ICD patients. Heart 2002; 87:488–93. doi./10.1136/heart.87.5.488

5. Irvine J, Dorian P, Baker B, et al. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J 2002;144:282–9. doi./10.1067/mhj.2002.124049

6. Amiraslanov A.Y., Artyukhina E.A., Revishvili A.S. Features of subcutaneous cardioverter-defibrillators implantation. Kazan medical journal 2023; 104(3): 367-380. (In Russ.) doi: 10.17816/KMJ109719

7. Taymasova I, Revishvili A. Evaluation of the effectiveness of interventional treatment of ventricular arrhythmias of rare localizations using non-invasive mapping. Patologiya Krovoobrashcheniya I Kardiokhirurgiya 2022; 26(1):73–82. (In Russ.) https://doi.org/10.21688/16813472-2022-1-73-82

8. Bokeria LA, Golukhova EZ, Popov SV, et al. 2020 Clinical practice guidelines for supraventricular tachycardia in adults. Russian Journal of Cardiology 2021;26(5):4484. (In Russ.) https://doi.org/10.15829/1560-4071-2021-4484

9. Dedukh EV, Yashkov MV, Artyukhina EA, Revishvili AS. Diagnostic potential of noninvasive mapping in the treatment of ventricular tachycardia in a patient with postinfarction scar: a case report. Cardiovascular Therapy and Prevention 2022;21(2):2947. (In Russ.) https://doi.org/10.15829/1728-8800-2022-2947

10. Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics–2021 update: a report from the American Heart Association. Circulation. 2021;143:e254–e743. DOI: 10.1161/CIR.0000000000000950

11. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6:606–619. DOI: 10.1161/HHF.0b013e318291329a

12. Fomin IV. Chronic heart failure in Russian Federation: What do we know and what to do. Russ J Cardiol. 2016;136(8):7-13. (In Russ.) doi: https://doi.org/10.15829/1560-4071-2016-8-7-13.

13. Agarwal MA, Fonarow GC, Ziaeian B. National trends in heart failure hospitalizations and readmissions from 2010 to 2017. JAMA Cardiol. 2021;6:952–956. doi./10.1001/jamacardio.2020.7472

14. Meyer S, Brouwers FP, Voors AA, et al. Sex differences in new-onset heart failure. Clin Res Cardiol. 2015;104(4):342-350. doi:10.1007/s00392014-0788-x

15. Brouwers FP, de Boer RA, van der Harst P, et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J. 2013;34(19):1424-1431. doi:10.1093/eurheartj/eht066

16. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789 1858. doi: 10.1016/S01406736(18)32279-7.

17. Khan MA, Hashim MJ, Mustafa H, et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus. 2020;12(7):e9349. doi:10.7759/cureus.9349.

18. Myerburg RJ, Junttila MJ. Sudden cardiac death caused by coronary heart disease. Circulation 2012;125:1043–1052. doi.org/10.1161/circulationaha.111.023846

19. Stecker EC, Reinier K, Marijon E, et al. Public health burden of sudden cardiac death in the United States. Circ Arrhythm Electrophysiol. 2014;7(2):212217. doi:10.1161/CIRCEP.113.001034

20. Chen LY, Sotoodehnia N, Bůžková P, et al. Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. JAMA Intern Med. 2013;173(1):29-35. doi:10.1001/2013.jamainternmed.744

21. Marijon E, Uy-Evanado A, Dumas F, et al. Warning Symptoms Are Associated With Survival From Sudden Cardiac Arrest. Ann Intern Med. 2016;164(1):23-29. doi:10.7326/M14-2342

22. Glinge C, Jabbari R, Risgaard B, et al. Symptoms Before Sudden Arrhythmic Death Syndrome: A Nationwide Study Among the Young in Denmark. J Cardiovasc Electrophysiol. 2015;26(7):761-767. doi:10.1111/jce.12674

23. Ågesen FN, Lynge TH, Blanche P, et al. Temporal trends and sex differences in sudden cardiac death in the Copenhagen City Heart Study. Heart. 2021;107(16):1303-1309. doi:10.1136/heartjnl-2020-318881

24. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349-1355. doi:10.1056/NEJM199605233342101

25. Tang PT, Shenasa M, Boyle NG. Ventricular Arrhythmias and Sudden Cardiac Death. Card Electrophysiol Clin. 2017 Dec;9(4):693-708. doi: 10.1016/j.ccep.2017.08.004.

26. McNally B, Robb R, Mehta M, et al. Out-ofhospital cardiac arrest surveillance --Cardiac Arrest Registry to Enhance Survival (CARES), United States, October 1, 2005--December 31, 2010. MMWR Surveill Summ. 2011;60(8):1-19.

27. ESC Scientific Document Group. Linee guida ESC 2022 per la gestione dei pazienti con aritmie ventricolari e la prevenzione della morte cardiaca improvvisa [2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death]. G Ital Cardiol (Rome). 2023;24(3 Suppl 1):e1e132. doi:10.1714/3986.39669

28. Desai AS, Mc Murray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015; 36: 1990–7. doi:10.1093/eurheartj/ehv186.

29. Writing Committee, Maddox TM, Januzzi JL Jr, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(6):772-810. doi:10.1016/j.jacc.2020.11.022

30. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure [published correction appears in N Engl J Med. 2005 May 19;352(20):2146]. N Engl J Med. 2005;352(3):225-237. doi:10.1056/NEJMoa043399

31. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-883. doi:10.1056/NEJMoa013474

32. Goldenberg I, Moss AJ, McNitt S, et al. Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006;47(9):1811-1817. doi:10.1016/j.jacc.2005.12.048

33. Connolly SJ, Hallstrom AP, Cappato R, et al. Metaanalysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21(24):2071-2078. doi:10.1053/euhj.2000.2476

34. Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337(22):1576-1583. doi:10.1056/NEJM199711273372202

35. Knackstedt C, Arndt M, Mischke K, et al. Depression, psychological distress, and quality of life in patients with cardioverter defibrillator with or without cardiac resynchronization therapy. Heart Vessels. 2014;29(3):364-374. doi:10.1007/s00380-0130372-8

36. Tatarskij RB, Mihajlov EN, Lebedeva VK, et al. Jekstrennaja kateternaja ablacija jelektricheskogo shtorma u bol’nyh s implantirovannymi kardioverterami-defibrilljatorami. Rossijskij kardiologicheskij zhurnal. 2015; 11(127): 57-62. (In Russ).

37. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007;357: 2657– 65 DOI: 10.1056/NEJMoa065457

38. Kuck K-H, Schaumann A, Eckardt L, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010;375: 31–40. doi./10.1016/s0140-6736(09)61755-4

39. Sapp JL, Wells GA, Parkash R, et al. Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. N Engl J Med. 2016;375(2):111121. doi:10.1056/NEJMoa1513614

40. Kuck K-H, Tilz RR, Deneke T, et al. Impact of substrate modification by catheter ablation on implantable cardioverter-defibrillator interventions in patients with unstable ventricular arrhythmias and coronary artery disease: results from the multicenter randomized controlled SMS (Substrate Modification Study). Circ Arrhythm Electrophysiol 2017;10:e004422. doi./10.1161/circep.116.004422

41. Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation. 2008;118(25):2773-2782. doi:10.1161/CIRCULATIONAHA.108.788604

42. Marchlinski FE, Haffajee CI, Beshai JF, et al. LongTerm Success of Irrigated Radiofrequency Catheter Ablation of Sustained Ventricular Tachycardia: Post-Approval THERMOCOOL VT Trial. J Am Coll Cardiol. 2016;67(6):674-683. doi:10.1016/j.jacc.2015.11.041

43. Pandian J, Kaur D, Yalagudri S, et al. Safety and efficacy of epicardial approach to catheter ablation of ventricular tachycardia An institutional experience. Indian Heart J. 2017;69(2):170-175. doi:10.1016/j.ihj.2016.10.010

44. Packer DL, Wilber DJ, Kapa S, et al. Ablation of Refractory Ventricular Tachycardia Using Intramyocardial Needle Delivered Heated SalineEnhanced Radiofrequency Energy: A First-in-Man Feasibility Trial. Circ Arrhythm Electrophysiol. 2022;15(8):e010347. doi:10.1161/CIRCEP.121.010347

45. Della Bella P, Baratto F, Vergara P, et al. Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial. Circulation. 2022;145(25):1829-1838. doi:10.1161/CIRCULATIONAHA.122.059598

46. Revishvili ASh, Ardashev AV, Boytsov SA, et al. Clinical guidelines for electrophysiological studies, catheter ablation and the use of implanted antiarrhythmic devices. All-Russian Scientific Society of Specialists in Clinical Electrophysiology, Arrhythmology and Cardiac Stimulation (VNOA). 3rd ed., Add. and revised M.:MAKS Press, Moscow, 2013: 596.(In Russ).

47. Chapurnykh AV, Nizhnichenko VB, Lakomkin SV, et al. Radiofrequency ablation of hemodynamically unstable postinfarction ventricular tachycardia. Kremlin medicine. Clinical Bulletin. 2015; 3: 126-134 (In Russ.).

48. Golanov AV. Stereotactic irradiation of CNS pathology using the CyberKnife. Monograph. Moscow 2017:32. (in Russ.)

49. Revishvili AS, Vaskovsky VA, Artyukhina EA, et al. Stereotactic radioablation in clinical practice for the treatment of a patient with ventricular tachycardia: case report. Journal of Arrhythmology. 2022;29(4):66-72. https://doi.org/10.35336/VA-20224-10

50. Vaskovskii VA, Taimasova IA, Artyukhina EA, et al. Long-Term Results of the First Clinical Application of Stereotactic Radioablation Using a Linear Electron Accelerator for the Treatment of Ventricular Tachycardia. Bull Exp Biol Med. 2023;174(5):594-600. doi: 10.1007/s10517-023-05753-x

51. Cuculich PS, Schill MR, Kashani R, et al. Noninvasive Cardiac Radiation for Ablation of Ventricular Tachycardia. N Engl J Med. 2017;377: 2325-2336. DOI: 10.1056/NEJMoa1613773.

52. Levine L. CyberHeart’s cardiac arrhythmia ablation treatment: patients with refractory ventricular tachycardia/fibrillation. ClinicalTrials. gov Identifier: NCT02661048.

53. Blanck O, Buergy D, Vens M, et al. Radiosurgery for ventricular tachycardia: preclinical and clinical evidence and study design for a German multicenter multiplatform feasibility trial (RAVENTA). Clin Res Cardiol. 2020 Nov;109(11): 1319-1332. DOI: 10.1007/s00392-02001650-9.